FILE - In this Friday, June 12, 2020 file photo, a doctor holds a bag of blood plasma donated by a COVID-19 survivor at at blood bank in La Paz, Bolivia. The U.S. Food and Drug Administration authorized the use of blood plasma for what’s called “emergency use” during the coronavirus pandemic, but the World Health Organization (WHO) on Monday AUG. 24, 2020, cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy. (AP Photo/Juan Karita, FILE)

UN cautions that coronavirus plasma treatment still experimental

FDA’s action was announced by U.S. President Donald Trump, who called it a ‘breakthrough’

The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

On Sunday, the U.S. Food and Drug Administration authorized what’s called “emergency use” of the treatment under its special powers to speed the availability of promising experimental drugs during a public health crisis. The action isn’t the same as approving plasma as safe and effective, and numerous rigorous studies are underway to find out if it really works.

So far, “The results are not conclusive,” WHO’s chief scientist Dr. Soumya Swaminathan said during a press briefing. “At the moment, it’s still very low-quality evidence.”

Convalescent plasma is a century-old treatment that was used to fight off flu and measles outbreaks in the days before vaccines, and was tried more recently during the Ebola outbreak. When the body encounters a new germ, it makes proteins called antibodies that are specially targeted to fight the infection. The antibodies float in plasma — the yellowish, liquid part of blood — which is collected from COVID-19 survivors and given to patients infected with coronavirus.

Swaminathan said WHO considered plasma therapy to be experimental and that it should continue to be evaluated. She said the treatment is difficult to standardize: Plasma must be collected individually, and people produce different levels of antibodies.

“Of course, countries can do an emergency listing if they feel the benefits outweigh the risks,” she said. “But that’s usually done when you’re waiting for the more definitive evidence.”

READ MORE: Trump announces plasma treatment authorized for COVID-19

In a letter describing the FDA’s emergency action, the agency’s chief scientist said the treatment “should not be considered a new standard of care” for coronavirus infections, and that more data from studies will be available in the coming months.

But already, so many COVID-19 patients have requested plasma rather than agreeing to be part of a research study that many scientists fear they won’t get a clear answer on whether the treatment really works — and if it does, how and when it should be used for the best outcomes.

Martin Landray, of the University of Oxford said that while the therapy offers “huge promise,” there was still no proof it works.

“There is a huge gap between theory and proven benefit,” he said in a statement.

If just a few thousand patients took part in the research “we would have the answer,” said Landray, who is conducting a plasma study in the U.K. “If effective, convalescent plasma could be rapidly used worldwide. If not, it could be abandoned,”

Stephen Griffin, an associate professor of medicine at the University of Leeds, said there was still considerable uncertainty about the immune system’s response to COVID-19, making any potential use of convalescent plasma challenging.

The FDA’s action was announced during a Sunday press briefing by U.S. President Donald Trump, who called it a “breakthrough.”

“It appears that the lessons from hydroxychloroquine have not been learned,” Griffin said, referring to the malaria drug touted by Trump and others as a potential treatment for the coronavirus.

The FDA also granted hydroxychloroquine an emergency authorization before suspending it months later after several trials showed the drug didn’t work against COVID-19 and raised the risk of heart, kidney, liver and other problems.

____

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Maria Cheng, The Associated Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

CoronavirusDonald TrumpUSA

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Bella Coola Heli Sports now offering yacht-based heliskiing starting at $319K

BCHS has partnered with Maple Leaf Adventures and the MV Cascadia

Liberals and Greens yet to announce North Coast candidates

North Coast candidates have until two weeks before the election to name contenders

Nimpkish sold as Northern Sea Wolf resumes central coast route

The sale of the Nimpkish was official as of Sept. 20, 2020

Citing stability, B.C. Premier calls snap election for Oct. 24

John Horgan meets with Lieutenant Governor to request vote

BC Timber Sales’ operations on the North Island and Central Coast to be audited

The Forest Practices Board randomly chose the region to check for compliance to legislation

Pandemic derails CP Holiday Train

Canadian Pacific will work to get donations to food banks while also producing an online music concert

Vanderhoof’s Brian Frenkel takes on top job in tough times

We can get through this, new local government leader says

Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

Local councils important, Horgan says as municipal conference ends

B.C. NDP leader says ‘speed dating’ vital, online or in person

Penticton woman sentenced to one year in prison for manslaughter of teen boyfriend

Kiera Bourque, 24, was sentenced for manslaughter in the 2017 death of Penticton’s Devon Blackmore

B.C. Green leader says NDP abandoning environmental plan

Horgan’s claim of unstable government false, Furstenau says

Transgender B.C. brothers debut fantasy novel as author duo Vincent Hunter

‘Transgender people are being misrepresented in popular fiction and media, and we aim to change that’

Most Read